How to buy Guardant Health stock | $104.34

Guardant Health, Inc is a diagnostics & research business based in the US. Guardant Health shares (GH) are listed on the NASDAQ and all prices are listed in US Dollars. Guardant Health employs 622 staff and has a trailing 12-month revenue of around USD$257.6 million.

How to buy shares in Guardant Health

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Guardant Health. Find the stock by name or ticker symbol: GH. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Guardant Health reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$104.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Guardant Health, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Guardant Health. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Guardant Health share price

Use our graph to track the performance of GH stocks over time.

Guardant Health shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$104.34
52-week range	USD$55.9 - USD$113.74
50-day moving average	USD$103.3912
200-day moving average	USD$87.9004
Wall St. target price	USD$116
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.281

Buy Guardant Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Guardant Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Guardant Health, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Guardant Health price performance over time

Historical closes compared with the close of $104.34 from 2020-11-16

1 week (2020-11-25)	-7.37%
1 month (2020-11-06)	-7.63%
3 months (2020-09-04)	14.90%
6 months (2020-06-05)	25.38%

1 year (2019-12-05)	41.80%
2 years (2018-12-04)	145.74%
3 years (2017-12-02)	N/A
5 years (2015-12-02)	N/A

Guardant Health financials

Revenue TTM	USD$257.6 million
Gross profit TTM	USD$143.7 million
Return on assets TTM	-7.47%
Return on equity TTM	-11.52%
Profit margin	-46.73%
Book value	$11.223
Market capitalisation	USD$10.1 billion

TTM: trailing 12 months

Shorting Guardant Health shares

There are currently 2.4 million Guardant Health shares held short by investors – that's known as Guardant Health's "short interest". This figure is 6.3% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Guardant Health shares can be evaluated.

Guardant Health's "short interest ratio" (SIR)

Guardant Health's "short interest ratio" (SIR) is the quantity of Guardant Health shares currently shorted divided by the average quantity of Guardant Health shares traded daily (recently around 894984.79087452). Guardant Health's SIR currently stands at 2.63. In other words for every 100,000 Guardant Health shares traded daily on the market, roughly 2630 shares are currently held short.

However Guardant Health's short interest can also be evaluated against the total number of Guardant Health shares, or, against the total number of tradable Guardant Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Guardant Health's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Guardant Health shares in existence, roughly 20 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Guardant Health shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Guardant Health.

Find out more about how you can short Guardant Health stock.

Guardant Health share dividends

We're not expecting Guardant Health to pay a dividend over the next 12 months.

Guardant Health share price volatility

Over the last 12 months, Guardant Health's shares have ranged in value from as little as $55.9 up to $113.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardant Health's is 0.5024. This would suggest that Guardant Health's shares are less volatile than average (for this exchange).

Guardant Health overview

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Frequently asked questions

• What percentage of Guardant Health is owned by insiders or institutions?

  Currently 8.443% of Guardant Health shares are held by insiders and 79.38% by institutions.

• How many people work for Guardant Health?

  Latest data suggests 622 work at Guardant Health.

• When does the fiscal year end for Guardant Health?

  Guardant Health's fiscal year ends in December.

• Where is Guardant Health based?

  Guardant Health's address is: 505 Penobscot Drive, Redwood City, CA, United States, 94063

• What is Guardant Health's CUSIP number?

  Guardant Health's Committee on Uniform Securities Identification Procedures number is: 40131M109